TX-SCHLUMBERGER-LIMITED
22.10.2019 22:40:40 CEST | Business Wire | Press release
Schlumberger Limited (“Schlumberger”) today announced that Schlumberger Holdings Corporation, an indirect wholly-owned subsidiary of Schlumberger (“SHC”), will redeem the entire outstanding principal amount of its 3.000% Senior Notes due 2020 (the “2020 Notes”), and that Cameron International Corporation, an indirect wholly-owned subsidiary of Schlumberger (“Cameron”), will redeem the entire outstanding principal amount of its 4.50% Senior Notes due 2021 (the “2021 Notes”) and the entire outstanding principal amount of its 3.60% Senior Notes due 2022 (the “2022 Notes” and, collectively with the 2020 Notes and the 2021 Notes, the “Notes”). The redemption date for each series of Notes is November 21, 2019 (the “Redemption Date”).
The aggregate principal amount of the 2020 Notes outstanding is $416,044,000, the aggregate principal amount of the 2021 Notes outstanding is $126,193,000 and the aggregate principal amount of the 2022 Notes outstanding is $105,779,000. The Notes will be redeemed on the Redemption Date at a redemption price for each series of Notes equal to (a) 100% of the aggregate principal amount being redeemed, plus (b) accrued and unpaid on such Notes from the last interest payment date to, but excluding, the Redemption Date, plus (c) a make-whole premium to be calculated three business days prior to the Redemption Date in accordance with the terms of the applicable series of Notes and the applicable indenture governing such series of Notes. On and after the Redemption Date, interest will cease to accrue on the Notes and the Notes will cease to be outstanding.
Notices of redemption are being sent by the applicable trustee for each series of Notes to all currently registered holders of such series of Notes.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the federal securities laws — that is, statements about the future, not about past, events. Such statements often contain words such as “expect,” “may,” “believe,” “plan,” “estimate,” “intend,” “anticipate,” “should,” “could,” “will,” “see,” “likely” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as statements regarding the terms and timing of the redemption of each series of Notes. Neither Schlumberger, SHC nor Cameron can give any assurance that such statements will prove correct. These statements are subject to, among other things, the risks and uncertainties detailed in Schlumberger’s most recent Forms 10-K, 10-Q, and 8-K filed with or furnished to the Securities and Exchange Commission. Actual outcomes may vary materially from those reflected in Schlumberger’s forward-looking statements. The forward-looking statements speak only as of the date made, and Schlumberger disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022006128/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Unveils AI-Native Platform for IT Financial Management30.4.2026 17:00:00 CEST | Press release
Brightfin clients drive their businesses forward with the first AI Native Cost Optimization Platform Brightfin, the only ITFM and Technology Expense Management solution built natively on ServiceNow, today announced an AI-Native architecture that fundamentally improves how organizations manage IT spend. Rather than bolting AI onto legacy systems, Brightfin has engineered intelligence from the ground up - starting with the data, building contextual awareness on top of it, and delivering AI agents that speak the language of IT finance. Brightfin’s unified budget-to-billing data model creates a stable, governed foundation that connects contracts, invoices, inventory, and budgets into a single source of truth - something no external ITFM tool or native platform module can replicate. This is a structured financial backbone purpose-built for enterprise IT spend, and it’s what makes everything above it possible. A context-aware, AI-Native, intelligence layer understands relationships across th
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 15:22:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et
Experian Announces Agent Trust to Power Trusted AI Driven Commerce30.4.2026 15:00:00 CEST | Press release
First-of-its-kind human-to-agent binding service for secure AI-driven commerce, developed with a growing ecosystem of agentic commerce collaborators, including Visa, Cloudflare and Skyfire Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430719198/en/ Experian Announces Agent Trust to Power Trusted AI Driven Commerce. As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust addresses this challenge through a new “Kn
Meet the AI-powered fan companion: TGR Haas F1 Team RaceMate powered by Infobip30.4.2026 15:00:00 CEST | Press release
New always-on conversational agent with team race intelligence, team insights, and interactive experiences powered by Infobip AgentOS Global AI-first cloud communications platform Infobip and TGR Haas F1 team are launching ‘TGR Haas F1 Team RaceMate powered by Infobip’, an AI-powered conversational fan companion on Apple Messages for Business and WhatsApp Business Platform. Always-on and always available, it delivers race intelligence for TGR Haas F1 Team: team race intelligence, grid positions, qualifying outcomes, sprint results, and full session schedules. The AI agent tracks drivers Ollie Bearman and Esteban Ocon with their individual championship standings and performance data in conversational format. The agent draws from a knowledge base covering driver biographies, team history, and circuit data, adapting to each user's knowledge level. Every interaction begins with a schedule check, ensuring fans always know what's happening right now. It proactively surfaces relevant informat
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
